Editorial ad in The Pathologist
An editorial advertisement about Lumito has been published in The Pathologist magazine. The aim is to increase awareness and interest in Lumito's product among pathologists internationally. The article appears in the October issue of both the print and digital editions. Here is a short abstract of the editorial advertisement, which is also attached. "Early and […]
Lumito AB publishes Quarterly Report 3, 2021
Financial overview Third quarter, January–September 2021 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -19,517 (-10,848). Basic and diluted earnings per share amounted to SEK -0.22 (-0.15). Cash flow from operating activities after change in working capital amounted to KSEK -19,927 (-12,239). Cash and cash equivalents amounted to KSEK […]
Correction of previously published press release concerning the early publication of the quarterly report
The press release published on 18 October at 13.00 contains incorrect information, as the Quarterly Report 3 2021 has not been audited. For further information, please contact: Lumito's CEO, Mattias Lundin e-mail: ml@lumito.se phone: 076-868 45 09 Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide […]
Earlier quarterly report in Lumito AB (publ)
Lumito AB (publ) hereby announces that the Board of Directors has decided to bring forward the company's report for quarter 3, 2021 to 20 October 2021, as the compilation work has progressed faster than expected and the auditors have reviewed the report. The Company's financial calendar has been updated and can be found here. For […]
Change of mentor to Mangold Fondkommission
Lumito AB has entered into an agreement with Mangold Fondkommission AB to act as the company's mentor in trading on NGM Nordic SME. Mangold Fondkommission will take over as mentor for the company on 15 October 2021. Lumito has simultaneously terminated the agreement with G&W Fondkommission AB, which expired on 14 October 2021. For further […]
Scanner with improved functionality installed
A life science consultant from TTP plc has delivered the next version of the Lumito’s scanner, with improved functionality, and assisted in the installation process. The new scanner entails, among other things, greater capacity to test new indications and to complete the evaluation of the breast cancer marker Her2. – Due to the pandemic, this was […]
Patent application approved in an additional country – Brazil
Lumito's (https://lumito.se/en/home/) basic patent, a patent in the first patent family protecting the use of upconverting nanoparticles (UCNPs) for imaging in scattering materials, such as human tissue, has now been approved in Brazil. Among other countries, the company is awaiting response to an application concerning India. – The approval of our basic patent is an important […]
Lumito develops the tissue diagnostics of the future – basic patent now granted in Europe
Lumito's product comprises an instrument and staining reagents based on UCNPs (up-converting nanoparticles). The instrument is intended for use in tissue diagnostics, to provide pathologists visual depictions of tissue samples as an input for making diagnosis. The technology is patented across three global patent families that cover the creation of high-quality imaging of tissue, for […]
Lumito AB publishes Quarterly Report 2, 2021
Financial overview of the second quarter and the half year Second quarter 2021, April 1 – June 30 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -6 619 (-4 202). Earnings per share before and after dilution amounted to SEK -0.08 (-0.06). Cash flow from operating activities after changes in […]
Patent approved also in India
The patent describing the use of light pulses to improve the efficiency of the technique and shorten imaging times has now also been granted in India. The patent has already been approved in Europe, South Korea, Australia, China, South Africa, USA and Japan and we are awaiting approval in Canada. – The grant of the […]
